Flow cytometric analysis of Mouse CD226 expression on C57BL/6 mouse splenocytes. C57BL/6 mouse splenocytes were stained with APC Rat Anti-Mouse CD8α Antibody and either Alexa Fluor® 488 Rat IgG2b, κ Isotype Control (Left panel) or SDT Alexa Fluor® 488 Rat Anti-Mouse CD226 Antibody (Right panel) at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Alexa Fluor® 488 Rat Anti-Mouse CD226 Antibody (S-R625)
Alexa Fluor® 488 Rat Anti-Mouse CD226 Antibody (S-R625)
Price:
Regular price
$60 USD
Regular price
Sale price
$60 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | CD226 |
| Synonyms | CD226 antigen; Platelet and T-cell activation antigen 1; Pta1; Cd226 |
| Location | Cell membrane |
| Accession | Q8K4F0 |
| Clone Number | S-R625 |
| Antibody Type | Rat mAb |
| Isotype | IgG2b,k |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | C57BL/6 mouse splenocytes |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 488 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Ms |
Background
CD226, also known as DNAM-1, is a transmembrane glycoprotein in the immunoglobulin superfamily that functions as a key co-stimulatory receptor on T cells, NK cells, monocytes, and platelets, where it binds the nectin-family ligands CD155 and CD112 to trigger phosphorylation of its intracellular tyrosine and serine residues, thereby recruiting LFA-1 and activating Src, PI3K-AKT, VAV1-ERK, and PLCγ2 signaling cascades that enhance immune synapse formation, cytotoxic granule release, and production of IFN-γ and other cytokines, thus promoting antiviral and antitumor immunity; its expression correlates with improved outcomes in cancer immunotherapy, while its genetic polymorphisms or down-regulation are linked to autoimmune diseases and tumor immune evasion, making CD226 an emerging target for immunomodulatory therapies.
Picture
Picture
FC
